Luteinizing hormone and progesterone concentrations and induction of estrus after use of norgestomet ear implants or constant infusion of gonadotropin-releasing hormone in anestrous, nonlactating dairy goats.
Plasma luteinizing hormone and progesterone concentrations, time to onset of estrus, and pregnancy rates were determined in nonlactating anestrous does given 1 of 4 treatments: subcutaneous ear implants containing 3 mg of norgestomet for 9 days (NOR; n = 6); subcutaneous administration, using osmotic minipumps, of 250 ng of gonadotropin-releasing hormone (GnRH)/h for 48 hours (GnRH; n = 6); 3 mg of NOR for 9 days, followed immediately by 250 ng of GnRH/h for 48 hours (NOR + GnRH; n = 6); or no treatment (control; n = 6). During the 72-hour period after removal of NOR or insertion of GnRH pumps, 6 of 6, 0 of 6, 6 of 6, and 3 of 6 does were observed in estrus at a mean (+/- 13.8) hours in groups NOR, GnRH, NOR + GnRH, and control, respectively. Time from end of treatment to peak concentrations of luteinizing hormone were 56 +/- 4.0, 28 +/- 4.7, 34 +/- 4.3, and 41 +/- 9.7 hours (mean +/- SE) for NOR, GnRH, NOR +/- GnRH, and control, respectively. Peak concentrations of luteinizing hormone were significantly greater and occurred significantly later in does given NOR. Progesterone concentrations in does that became pregnant increased to concentrations greater than or equal to 1.0 ng/ml 3 to 5 days after breeding and remained high. Functional corpora lutea (CL) was found in 6 does that did not become pregnant, 1 CL was associated with pseudopregnancy and 1 CL was associated with ovulation prior to placement of the GnRH pumps. Functional CL failed to form in 10 of the 12 doses in groups GnRH and control.(ABSTRACT TRUNCATED AT 250 WORDS)
Bretzlaff
K N
KN
Department of Large Animal Medicine and Surgery, Texas A & M University, College Station 77843.
Nuti
L C
LC
Scarfe
A D
AD
Elmore
R G
RG
Capehart
J
J
Varner
D D
DD
Weston
P G
PG
D000818:Animals; D003338:Corpus Luteum / Q000187:drug effects / Q000502:physiology; D004343:Drug Implants; D004971:Estrus / Q000187:drug effects*; D005260:Female; D005298:Fertility / Q000187:drug effects; D006041:Goats / Q000097:blood / Q000502:physiology*; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000494:pharmacology*; D007260:Infusion Pumps / Q000662:veterinary; D007263:Infusions, Parenteral / Q000662:veterinary; D007986:Luteinizing Hormone / Q000097:blood; D010060:Ovulation / Q000187:drug effects; D011282:Pregnenediones / Q000008:administration & dosage / Q000494:pharmacology*; D011374:Progesterone / Q000097:blood; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000494:pharmacology*; D011897:Random Allocation
D004343:Drug Implants; D011282:Pregnenediones; D045167:Progesterone Congeners; D007987:Gonadotropin-Releasing Hormone; C100284:norgestomet; D011374:Progesterone; D007986:Luteinizing Hormone